Literature DB >> 25173939

Neurological antiphospholipid syndrome: Clinical, neuroimaging, and pathological characteristics.

De-Sheng Zhu1, Jue Fu2, Yue Zhang3, Shi-Xu Li3, Guang-Xian Zhang4, Yang-Tai Guan5, Qiang Dong6.   

Abstract

BACKGROUND: Neurological antiphospholipid syndrome (NAPS) is often misdiagnosed or missed. Only limited clinical and neuroimaging information about it is available, and the pathological characteristics was rarely reported before. This study aimed to explore the clinical, neuroimaging, and pathological characteristics of NAPS.
METHODS: We performed a retrospective analysis of 51 patients with APS, categorized into NAPS (n = 16) and rheumatology antiphospholipid syndrome (RAPS) groups (n = 35). Demographics and clinical profile were compared between the two groups, and the neuroimaging and pathological information of NAPS was also analyzed.
RESULTS: The mean age of the NAPS patients, 81.25% of whom were female, was 37.56 ± 12.36 years, and the average duration was 1.32 ± 0.96 years (range = 18 days to 3.5 years). No significant differences in age, sex, disease duration, classification, and comorbidities at baseline were observed between NAPS and RAPS patients (p > 0.05). Chief complaint of headache and thromboembolic events was higher in NAPS patients than in RAPS patients (p<0.05). Neuroimaging detected multiple infarcts and demyelination lesions were distributed in subcortical and cortical area asymmetrically. Skin biopsy examination showed small vessel occlusion with inflammatory cells, while brain biopsy examination showed erythrocyte accumulation with some neuron degeneration and local demyelization. Antithrombotic and immunosuppressive therapy proved to be effective.
CONCLUSION: Headache and thromboembolic events are more common in NAPS than RAPS. Neuroimaging and biopsy examination demonstrated that NAPS is an ischemic cerebrovascular disease caused by vascular stenosis or occlusion. These characteristics might help to reduce the misdiagnosis of NAPS.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antiphospholipid antibodies; Antiphospholipid syndrome; Central nervous system; Clinical features; Neuroimaging; Pathology

Mesh:

Year:  2014        PMID: 25173939     DOI: 10.1016/j.jns.2014.08.010

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  7 in total

1.  Chronic relapsing inflammatory optic neuropathy in a patient with triple antiphospholipid antibody positivity.

Authors:  Cristian Eduardo Navarro; Gabriel José Arango; María F Cubides
Journal:  Neurol Sci       Date:  2021-04-20       Impact factor: 3.307

Review 2.  Non-stroke Central Neurologic Manifestations in Antiphospholipid Syndrome.

Authors:  Cécile M Yelnik; Elizabeth Kozora; Simone Appenzeller
Journal:  Curr Rheumatol Rep       Date:  2016-02       Impact factor: 4.592

Review 3.  Antiphospholipid syndrome (APS) revisited: Would migraine headaches be included in future classification criteria?

Authors:  Mohammad Hassan A Noureldine; Ali A Haydar; Ahmad Berjawi; Rody Elnawar; Ahmad Sweid; Munther A Khamashta; Graham R V Hughes; Imad Uthman
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

4.  Rapidly progressive intracranial artery stenosis in primary antiphospholipid syndrome.

Authors:  Christian L Seifert; Markus C Kowarik; Klaus Thürmel; Achim Berthele; Sascha Prothmann; Silke Wunderlich
Journal:  Ann Clin Transl Neurol       Date:  2015-05-25       Impact factor: 4.511

5.  The presence of non-criteria manifestations negatively affects the prognosis of seronegative antiphospholipid syndrome patients: a multicenter study.

Authors:  Gilberto Pires da Rosa; Bernardo Sousa-Pinto; Ester Ferreira; Olga Araújo; Giuseppe Barilaro; Paulo Bettencourt; Ricard Cervera; Gerard Espinosa
Journal:  Arthritis Res Ther       Date:  2022-01-03       Impact factor: 5.156

Review 6.  Headache and immunological/autoimmune disorders: a comprehensive review of available epidemiological evidence with insights on potential underlying mechanisms.

Authors:  Leonardo Biscetti; Gioacchino De Vanna; Elena Cresta; Ilenia Corbelli; Lorenzo Gaetani; Letizia Cupini; Paolo Calabresi; Paola Sarchielli
Journal:  J Neuroinflammation       Date:  2021-11-08       Impact factor: 8.322

7.  Cognitive dysfunction and associated neuroimaging biomarkers in antiphospholipid syndrome: a systematic review.

Authors:  Claire Donnellan; Hannah Cohen; David J Werring
Journal:  Rheumatology (Oxford)       Date:  2021-12-24       Impact factor: 7.580

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.